Study of Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 80
Summary
- Conditions
- Advanced Solid Tumors
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 75 years
- Gender
- Both males and females
Description
The study population is about 200 patients with advanced solid tumors, who fails or cannot tolerate standard therapies, or for whom no effective standard therapy is available, or who refuses standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated and Toripalimab 240mg wil...
The study population is about 200 patients with advanced solid tumors, who fails or cannot tolerate standard therapies, or for whom no effective standard therapy is available, or who refuses standard therapies. Surufatinib 250 mg once a day (QD) will be orally administrated and Toripalimab 240mg will be intravenously administered every 3 weeks up to documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. For Toripalimab, the upper time limit for treatment is 2 years. The primary objective is safety of safety run-in (about 6 patients) and objective response rate (ORR) of Surufatinib combined with Toripalimab in patients with advanced solid tumors.
Tracking Information
- NCT #
- NCT04169672
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Lin Shen Beijing Cancer Hospital